<DOC>
	<DOCNO>NCT00947141</DOCNO>
	<brief_summary>This study aim determine : ) whether patient 'low level ' viral load result ( 200 3,000 copies/ml ) could monitor opposed start preemptive therapy valganciclovir , ganciclovir and/or foscarnet ; b ) whether patient 'high level ' viral load result ( 3,000 copies/ml ) could stop preemptive therapy earlier , thus maximise benefit therapy minimising risk .</brief_summary>
	<brief_title>Determining Viral Load Threshold Treating Cytomegalovirus ( CMV )</brief_title>
	<detailed_description>Background Study Rationale In transplant recipient CMV infection , risk develop CMV disease directly proportional CMV DNA viral load . Historically The Royal Free , Hampstead , patient give preemptive therapy basis two consecutive positive CMV PCR result detect qualitative PCR technique . With introduction real time PCR , use Taqman probe ABI7700 thermal cycler , possible obtain rapid sensitive result viral load clinical sample low limit detection 200 copies/ml . Thus , viral load data incorporate clinical management patient . From natural history data , show patient CMV disease CMV PCR load range 14,000 203 million ( median 175,500 ) . The low bound 95 % confidence limit distribution 37,000 copies/ml aim initiate therapy time prevent CMV viral load reach value . To give margin safety , bear mind 1 day average doubling-time CMV timing sample twice-weekly , therefore recommend preemptive therapy give viral load increase 3,000 copies/ml . In past , patient CMV PCR load 200 3,000 copies/ml receive preemptive treatment previous PCR assay give quantitative result . As treatment associate side effect neutropaenia ( ganciclovir ) renal impairment ( foscarnet ) would preferable avoid unnecessary exposure possible . This study aim determine : ) whether patient 'low level ' viral load result ( 200 3,000 copies/ml ) could monitor opposed start preemptive therapy valganciclovir , ganciclovir and/or foscarnet ; b ) whether patient 'high level ' viral load result ( 3,000 copies/ml ) could stop preemptive therapy earlier , thus maximise benefit therapy minimising risk . Objectives Primary Objectives 1 . To define number patient Group A low level CMV reactivation subsequently develop viral load great 3000 copies/ml . 2 . To define number patient Group B develop second episode viral load 3000 copies/ml therapy discontinue defined viral load cut-offs . Secondary Objectives 1 . To define duration antiviral therapy need treat CMV viraemia . 2 . To record rate increase viral load prior start preemptive therapy . 3 . To correlate viral load CMV specific immune function .</detailed_description>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Viremia</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<mesh_term>Valganciclovir</mesh_term>
	<mesh_term>Foscarnet</mesh_term>
	<mesh_term>Phosphonoacetic Acid</mesh_term>
	<mesh_term>Ganciclovir triphosphate</mesh_term>
	<criteria>1 . All Stem Cell , Renal Liver Transplant recipient . 2 . Willing give inform consent . 3 . For Group A ) All patient CMV viraemia ( 200 3000 copies/ml ) liver , renal stem cell group two consecutive sample &amp; Group B ) Those patient require preemptive therapy viral load &gt; 3,000 copies/ml . 4 . All patient either section study must available CMV PCR monitoring least twice per week . 1 . Exclusion Criteria 2 . Profound neutropaenia consider preclude administration ganciclovir profound renal failure consider preclude administration foscarnet . 3 . Inability give inform consent . 4 . In stem cell group , Donor negative , Recipient negative transplant . 5 . In stem cell group : match unrelated donor CMV seronegative . 6 . Those patient Group A enter Group B part . study . 5.2.6 Those patient Group B enter Group A part study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Optimising treatment cytomegalovirus infection</keyword>
</DOC>